Prognosis from Pixels: A Vendor-Protocol-Specific CT-Radiomics Model for Predicting Recurrence in Resected Lung Adenocarcinoma.
Academic Article
Overview
abstract
BACKGROUND: Radiomics can provide quantitative descriptors of tumor phenotype, but translation is often limited by feature instability across scanners and protocols. We aimed to develop and internally validate a protocol-specific CT-radiomics model using preoperative imaging to predict 5-year recurrence in patients with stage I lung adenocarcinoma after complete surgical resection. METHODS: The retrospective study included 270 patients with completely resected stage I lung adenocarcinoma from January 2010-December 2021, among whom 23 (8.5%) experienced recurrence within five years. Radiomic features were extracted from routine preoperative CT scans. After preprocessing to remove highly constant and highly correlated features, the Synthetic Minority Over-sampling Technique addressed class imbalance in the training set. Recursive Feature Elimination identified the most predictive radiomic features. An XGBoost classifier was trained using optimized hyperparameters identified through RandomizedSearchCV with cross-validation. Model performance was evaluated using the ROC curve and predictive metrics. RESULTS: Five radiomic features differed significantly between recurrence groups (p = 0.007 to <0.001): Shape Sphericity, first-order 90Percentile, GLCM Autocorrelation, GLCM Cluster Shade, and GLDM Large Dependence Low Gray Level Emphasis. The radiomics model showed excellent discriminatory ability with AUC values of 0.99 (95% CI: 0.98-1.00), 0.97 (95% CI: 0.91-1.00), and 0.96 (95% CI: 0.85-1.00) on the training, validation, and test sets, respectively. On the test set, the model achieved sensitivity of 100% (95% CI: 51-100%), specificity of 94% (95% CI: 81-98%), PPV of 67% (95% CI: 30-90%), NPV of 100% (95% CI: 90-100%), and overall accuracy of 95% (95% CI: 83-99%). CONCLUSIONS: Under protocol-homogeneous imaging conditions, CT radiomics accurately predicted recurrence in patients with completely resected stage I lung adenocarcinoma. External multi-vendor validation is needed before broader deployment.
